Product Description
A substance being studied in the treatment of certain types of cancer, including non-Hodgkin lymphoma, breast, colon, lung, ovarian, and prostate. Enzastaurin hydrochloride blocks certain cell signaling pathways, and may prevent the growth of new blood vessels that tumors need to grow. It is a type of serine threonine kinase inhibitor and a type of antiangiogenesis agent. Also called LY317615. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/enzastaurin-hydrochloride)
Mechanisms of Action: PKC Beta Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Ehlers-Danlos SyndromeFast Track - GlioblastomaOrphan Drug - Ehlers-Danlos Syndrome *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, China, El Salvador, France, Germany, Ireland, Italy, Netherlands, Spain, Sweden, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 9
Highest Development Phases
Phase 3: Diffuse Large B-Cell Lymphoma|Ehlers-Danlos Syndrome|Environmental Hypersensitivity|Glioblastoma|Peanut Hypersensitivity
Phase 2: Hyperpigmentation
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PREVEnt (Prevention of Rupture with Enzastaurin in Vascular Ehlers-Danlos Syndrome Trial) | P3 |
Active, not recruiting |
Ehlers-Danlos Syndrome |
2025-08-30 |
|
| PREVEnt | P3 |
Suspended |
Ehlers-Danlos Syndrome |
2025-06-01 |
72% |
| DB102-01 | P3 |
Completed |
Glioblastoma |
2024-02-29 |
35% |
| ARC008 | P3 |
Completed |
Environmental Hypersensitivity|Peanut Hypersensitivity |
2023-04-27 |
70% |